Loading…
Loading…
Electromedical Technologies (OTC: EMED) outlines key financial restructuring milestones, upcoming product updates, and new strategic partnerships to drive sustainable growth in the pain management market. SCOTTSDALE, ARIZONA / ACCESS Newswire / August 6, 2025 / Electromedical Technologies, Inc. ("Electromedical" or the "Company") (OTC:EMED), a developer and manufacturer of FDA-cleared electrotherapy devices for pain management, today issued a mid-year update reflecting key steps taken to strengthen its financial position and advance core initiatives.
Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology. SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / Electromedical Technologies, Inc. (OTC PINK:EMED) - Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology.
Electromedical (EMED), a Leader in Bioelectronic Medical Devices, Updates Shareholders on Recent Achievements and Strategic Advancements SCOTTSDALE, AZ / ACCESSWIRE / August 8, 2024 / Electromedical (OTC PINK:EMED), a leading innovator in bioelectronic medical devices, is pleased to provide an update to its shareholders, highlighting significant recent achievements and strategic advancements. EMED Logo Sales Growth: 17% increase in revenue in year ended 2023 over year ended in 2022.
Electromedical Announces $1.36M Net Proceeds from Building Sale to Fund WellnessPro Infinity™ Launch and Convertible Note Retirement SCOTTSDALE, Ariz., March 22, 2023 /PRNewswire/ — Electromedical Technologies, Inc. (OTCQB: EMED) (“Electromedical” or the “Company”), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, […]...
SCOTTSDALE, Ariz., Sept. 30, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.
SCOTTSDALE, Ariz., Aug. 19, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, clarifies and corrects its previously published press release disclosing comparative results from the six months ended June 30, 2021 versus June 30, 2020.
SCOTTSDALE, Ariz., Aug. 18, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it recorded strong results for the second quarter of 2021, ending June 30, as compared to the same period in 2020.
•The Stage I research program now includes development of targeted Alzheimer's Disease therapy using bioelectronics •Experienced neuroscientist Dr. Sholpan Askarova to lead neuromodulation research program •Key objective is identification of electrical frequencies with a neuroprotection potency •Novel approach could emerge as alternative Alzheimer's Disease therapy to current, ineffective pharmaceuticals •Global therapy market is huge, estimated to reach $13.3 billion in 2023 •The Stage I research program now includes development of targeted Alzheimer's Disease therapy using bioelectronics •Experienced neuroscientist Dr. Sholpan Askarova to lead neuromodulation research program •Key objective is identification of electrical frequencies with a neuroprotection potency •Novel approach could emerge as alternative Alzheimer's Disease therapy to current, ineffective pharmaceuticals •Global therapy market is huge, estimated to reach $13.3 billion in 2023
No recent filings indexed.